All patients
autoimmune disease
Hydrocortisone in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
1.03 [0.54 ; 1.98 ] REMAP-CAP, fixed 7-day course, 2020 1 0% 236 NA not evaluable deathsdetailed results CAPE-COVID, 2020 0.45 [0.20; 1.02]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
0.71 [0.35 ; 1.43 ] CAPE-COVID, 2020, REMAP-CAP, fixed 7-day course, 2020 2 59% 387 moderate not evaluable deaths (time to event analysis only)detailed results REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
0.94 [0.61 ; 1.45 ] REMAP-CAP, fixed 7-day course, 2020 1 0% 238 NA not evaluable clinical improvementdetailed results REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
1.43 [0.91 ; 2.26 ] REMAP-CAP, fixed 7-day course, 2020 1 0% 278 NA not evaluable clinical improvement (14-day)detailed results REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
1.29 [0.82 ; 2.03 ] REMAP-CAP, fixed 7-day course, 2020 1 0% 238 NA not evaluable death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
1.35 [0.36 ; 5.08 ] CAPE-COVID, 2020, REMAP-CAP, fixed 7-day course, 2020 2 84% 247 moderate not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
1.67 [0.87 ; 3.19 ] CAPE-COVID, 2020 1 0% 149 NA not evaluable mechanical ventilationdetailed results CAPE-COVID, 2020 0.95 [0.44; 2.04]
0.95 [0.44 ; 2.04 ] CAPE-COVID, 2020 1 0% 149 NA not evaluable serious adverse eventsdetailed results REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
3.01 [0.33 ; 27.32 ] REMAP-CAP, fixed 7-day course, 2020 1 0% 238 NA not evaluable superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
0.81 [0.49 ; 1.34 ] CAPE-COVID, 2020 1 0% 149 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-13 09:05 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 737
- roots T: 290